ArticleCell death discovery2026
High-throughput strategy for targeting MDM2 in uveal melanoma to reverse radiation therapy resistance.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma (UM) presents a formidable clinical challenge due to its marked resistance to radiotherapy. In this study, an integrative strategy combining machine learning models with high-throughput screening platforms was employed to identify novel small-molecule inhibitors targeting MDM2, with the aim of overcoming this intrinsic resistance. Transcriptome sequencing and machine learning analysis identified MDM2 as a critical gene associated with UM radiotherapy resistance. Integration of single-cell RNA sequencing data revealed key cells contributing to this resistance. In vitro experiments demonstrated that the MDM2 inhibitor SAR405838 effectively increased radiosensitivity in resistant UM cells by modulating p53 activation, suppressing cell migration and invasion, and inducing DNA damage and apoptosis. This novel approach offers a promising therapeutic strategy for combating UM resistance to radiation therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.